Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083382 | 0.88 | LRRK2 (0.45) | HCRTR1DRD2DRD4DRD3LRRK2 | |
| SCHEMBL25018461 | 0.79 | LRRK2 (0.36) | LRRK2 | |
| SCHEMBL21849260 | 0.79 | — | — | |
| SCHEMBL25019041 | 0.79 | LRRK2 (0.37) | LRRK2 | |
| SCHEMBL25533085 | 0.77 | MPO (0.35) | LRRK2 | |
| SCHEMBL25018462 | 0.77 | LRRK2 (0.37) | LRRK2PDE4D | |
| SCHEMBL21258472 | 0.75 | DRD2 (0.39) | DRD2DRD4DRD3LRRK2GABRA1 | |
| SCHEMBL17173659 | 0.73 | DRD2 (0.30) | DRD2DRD4DRD3PDE4D | |
| SCHEMBL25356330 | 0.72 | DRD2 (0.37) | DRD2DRD4DRD3LRRK2GABRA1 | |
| SCHEMBL20689124 | 0.72 | KDM5A (0.42) | DRD2DRD4DRD3LRRK2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HCRTR1 309/4885DRD2 559/4885DRD4 1614/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HCRTR1 422/4885DRD2 955/4885DRD4 1861/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | HCRTR1 3726/4885DRD2 1561/4885DRD4 2796/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | HCRTR1 4769/4885DRD2 4707/4885DRD4 4848/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HCRTR1 309/4885DRD2 559/4885DRD4 1614/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | HCRTR1 3726/4885DRD2 1561/4885DRD4 2796/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | HCRTR1 422/4885DRD2 955/4885DRD4 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.